In conclusion, we demonstrated the role of baseline uEGF/MCP1 as a non-invasive pathophysiological biomarker that can be used with other conventional risk markers in the clinical setting for risk stratification in ADPKD patients. This evidence concerns the gene CCL2 and autosomal dominant polycystic kidney disease.